Any feedback?
Literature summary for 3.2.1.22 extracted from
- Agalsidase alfa and kidney dysfunction in Fabry disease (2009), J. Am. Soc. Nephrol., 20, 1132-1139.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | in male patients with Fabry disease, an X-linked disorder of glycosphingolipid metabolism caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, treatment with agalsidase alfa, i.e. alpha-galactosidase A produced by gene activation in a human cell line, does not affect proteinuria. Agalsidase alfa may stabilize kidney function | Homo sapiens |
Localization
| Localization | Comment | Organism | GeneOntology No. | Textmining |
|---|
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
male patients with Fabry disease | - |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| Agalsidase alfa | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
